Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

73.050
-0.500-0.68%
Volume:2.62M
Turnover:191.18M
Market Cap:21.84B
PE:-38.25
High:74.800
Open:73.500
Low:71.000
Close:73.550
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.75
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:4.66
PE(LYR):-38.25
PS:22.39

Loading ...

KEYMED BIO-B Shares Surge Over 9% Intraday as Dual-Antibody Drug CM512 Designated for Breakthrough Therapy

Stock News
·
Jul 15

Movement Alert|Keymed Biosciences Rises 5.08% in Regular Trading, Core Product Included in New National Essential Drug List with Multiple Brokerages Maintaining Buy Ratings

Market Focus
·
Jul 15

GTHT Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target

Deep News
·
Jul 09

Guotai Haitong Securities Initiates Coverage on KEYMED BIO-B with Buy Rating and HK$138.91 Price Target

Stock News
·
Jul 09

Innovative Drug Sector Maintains Upward Momentum on Favorable Regulatory Developments and Accelerating Internationalization

Stock News
·
Jul 06

Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%

Tiger Newspress
·
Jul 06

Movement Alert|Keymed Biosciences Rises 5.16% in Regular Trading, Dual Insurance Directory Policy and Two New Drug Clinical Approvals Fuel Gains

Market Focus
·
Jul 06

Movement Alert|Keymed Biosciences Rises 5.34% in Regular Trading, Dual Insurance Directory Policy and Long-Acting AD Track Valuation Reshaping Drive Continued Rally

Market Focus
·
Jul 03

Movement Alert|Keymed Biosciences Rises 9.4% in Regular Trading, Dual Medical Insurance Directory Policy Catalyzes Long-Acting AD Track Revaluation

Market Focus
·
Jul 02

Movement Alert|Keymed Biosciences Rises 5.46% in Regular Trading, AbbVie USD 10.9 Billion Apogee Acquisition Continues to Catalyze Long-Acting AD Track Valuation

Market Focus
·
Jun 29

Keymed Biosciences: All AGM Resolutions Secure Approval; Shareholders Signal Overwhelming Confidence

Bulletin Express
·
Jun 26

Keymed Biosciences Shareholders Approved All AGM Resolutions in Poll Vote

Reuters
·
Jun 26

Movement Alert|Keymed Biosciences Intraday Rise 5.65%, AbbVie Billion-Dollar Apogee Acquisition Continues to Catalyze Long-Acting AD Pipeline

Market Focus
·
Jun 26

Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies

Stock News
·
Jun 23

Jinrui Securities Maintains Buy Rating on KEYMED BIO-B, Citing Validation of Long-Acting AD Drug Value by Major Pharma Deal

Stock News
·
Jun 23

Movement Alert|CanNova-B Rises 5.38% in Regular Trading, AbbVie 10.9 Billion Dollar Apogee Acquisition Validates Long-Acting AD Product Value

Market Focus
·
Jun 23

Keymed Bio-B Shares Surge Over 6% in Morning Trading Following AbbVie's Major Acquisition

Stock News
·
Jun 23

KEYMED BIO-B Surges Nearly 6% on Completion of Ouro Medicines Acquisition Deal and Receipt of $257 Million Initial Payment

Stock News
·
Jun 12

Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close

MT Newswires Live
·
Jun 05

KEYMED BIO-B Receives Initial $257 Million Payment from Sale of Ouro Medicines Stake

Stock News
·
Jun 05